1 min read

Let’s Talk Medtech & CLEERLY

It’s American Heart Month, and Cleerly, a startup that uses artificial intelligence to change the way we diagnose cardiovascular disease is keeping busy.

Dr. James Min, founder and CEO of Cleerly, joins us on this episode of Let’s Talk Medtech for a riveting discussion about cardiovascular disease during American Heart Month.

Dr. James, “Jim” Min, founder and CEO of Cleerly, joins us on this episode of Let's Talk Medtech for a discussion about American Heart Month and the company’s goals over the next few months.

Cleerly’s  technology was born out of research from the Dalio Institute for Cardiovascular Imaging at the New York-Presbyterian Hospital and Weill Cornell Medicine and uses non-invasive coronary (CT) angiography to perform comprehensive coronary artery phenotyping through AI-enabled and FDA-cleared solutions.

This technology is based on millions of annotated lab images used to build more than two dozen algorithms capable of quantifying and characterizing the presence, extent, severity, and type of coronary artery disease and other cardiovascular disorders. Read full article HERE.

MedTech Strategist: Cleerly’s Personalized Approach to Heart Attack Risk

In this interview, Cleerly Founder and CEO, James Min, MD, shares how despite advances in cardiology, most heart attacks occur without warning....

Read More

Cleerly's AI scans comparable to gold-standard angiography

Only a few months after it emerged from stealth and burst onto the medtech scene, Cleerly is already living up to its name.

Read More

Cleerly’s Technology | An Important Impact On Our Overall Wellness

Health Tech: Dr James Min On How Cleerly’s Technology Can Make An Important Impact On Our Overall WellnessAn Interview With Dave Philistin

Read More